Australian and New Zealand College of Anaesthetists

Faculty of Pain Medicine

Project Grant Application Guide
(including Simulation/Education Grant)

2018

ADVICE AND INSTRUCTIONS TO APPLICANTS

To be used in conjunction with Project Grant Application Form

CLOSING DATE: 5 PM AEDT April 1, 2017

Research and Administration Coordinator
Australian and New Zealand College of Anaesthetists
research@anzca.edu.au
Ph: 61 3 8517 5336
IMPORTANT POINTS FOR COMPLETING ANZCA GRANT APPLICATIONS

• Read the ANZCA Research Grant Policy before completing the application form (http://www.anzca.edu.au/fellows/Research/anzca-research-information.html)

• An ANZCA REGKEY must be obtained and included in the header of the application form. Double-click on the header to add your REGKEY. Contact Susan Collins (email: research@anzca.edu.au) to obtain your REGKEY.

• Do not include or copy the cover sheet. Start your application with the page headed “In confidence”.

• A font size no smaller than 10 point may be used. The minimum margin is 2cm.

• You may add rows to tables where this is allowed in these guidelines (e.g. list of chief investigators, list of current research grants). Do not exceed prescribed word/page counts. Text that exceeds prescribed word counts will not be considered.

• Ensure that each page is numbered consecutively in the application.

• A written quotation for equipment costing $A10,000 or more, as requested in the budget section, must be attached to each copy of the application.

• The application must be submitted electronically via email to research@anzca.edu.au. Only files of 6MB or less will be accepted.

  o The electronic copy of the complete application including the signature page with scanned or electronic signatures (via email)

• Electronic copies must be in PDF format (converted word files only, not scanned documents) or Microsoft word format. Note for older versions on Microsoft Word please install the official update from http://www.microsoft.com/download/en/details.aspx?id=9943. This update will allow Microsoft office 2007 to save documents to .PDF format.

• The complete application must be received by the Research and Administration Coordinator by 5PM AEDT on the closing date for applications.

• Late applications WILL NOT BE ACCEPTED.

• Incomplete applications or those that do not follow these guidelines WILL NOT BE ACCEPTED.

• ANZCA cannot amend an application once it has been submitted.
A. CONDITIONS OF ANZCA GRANTS

1 Payment
Sums awarded will be paid upon request after January 1 each year for the duration of the grant. All payments will be made in Australian dollars, upon receipt of a fully correct tax invoice from the administering institution.

2 Conditions of professional research personnel
The conditions for professional research personnel shall be those of the institution in which the work is carried out or as the College may determine in particular circumstances. This includes annual leave and sick leave. However, the College does not provide for long service leave.

3 Alterations in research program budget
The CIA is expected to adhere to the approved research program or budget, and to notify any absences other than for short periods (e.g. three to four weeks). Full details of any proposed major alterations to either program or budget, or of any absences during the course of the grant, must be submitted in advance by the CIA to the Research and Administration Coordinator for approval by the Chair of the Research Committee (or his or her delegate).

4 Reporting requirements
Eligibility to apply for future funding will be contingent on complying with the reporting requirements of the ANZCA Grant Agreement Terms and Conditions. Unless otherwise specified, grants are awarded for the period of two calendar years following the year of the grant decision. The CIA may request in writing a time-only extension or roll-over of funds if the project is not completed at the end of the two-year period.

4.1 Progress report
The CIA is required to forward a progress report on the approved form to the College, by September 1 in each year of the award. This form can be found on the ANZCA website. If a progress report is not received by the due date, any funding for multi-year projects may be withheld and/or any future funding requested in subsequent years by the CIA may not be considered.

4.2 Final report
The CIA is required to forward a final report on the approved form to the College, within three months of the completion of the project. This form can be found on the ANZCA website. The final report must include a statement of expenditure charged to the grant. Any unexpended balance of the grant must be returned to the College and not be used on other projects.

5 Publications and presentations
The College requires that its contribution be acknowledged in all publications and presentations of the research project, for example “This study was supported by a grant from the ANZCA Research Foundation; Australian and New Zealand College of Anaesthetists” and that a presentation relating to the project be made at a major College meeting. A hard copy or pdf of the reprint must be sent to the Research and Administration Coordinator. If the protocol is registered with a journal or other relevant organisation, the College must receive a copy of the registration certificate.

6 Patents
Any discovery arising out of work supported by the College must not be the subject of application for patent except with the written approval of the College and the agreement of the institution in which the work is carried out.

7 Audit of research projects
In accordance with the ANZCA Academic Integrity Policy, available on the website, ANZCA reserves the right to conduct a random audit of ANZCA-funded research through the administering institution’s research office.

8 Termination of grant
A grant may be terminated if the conditions of the grant are not observed. A grant will terminate, unless other arrangements satisfactory to the College are made, if the CIA leaves the institution before the expiry of the grant. In such an eventuality, the recipient and the head of the department are expected to notify the College CEO. When a grant terminates any unexpended balance must be returned to the College.
B. GENERAL INFORMATION FOR APPLICANTS

1 Introduction
Funding for medical research in Australia, New Zealand, Hong Kong, Malaysia and Singapore is necessary if medical science is to maintain a high international standing. The most important single national source of funding for medical research in Australia is provided by the Commonwealth government through the Medical Research Endowment Fund, which is administered by the National Health and Medical Research Council (NHMRC). In New Zealand, funding is administered by the Health Research Council (HRC).

The NHMRC provides the opportunity for individuals or research teams to obtain support for research projects in all fields of public health, medicine and dentistry in Australia, through the Project Grant and Fellowship schemes. In New Zealand the HRC serves an equivalent role. The award of a project grant is ANZCA’s main avenue for the support of projects in biomedical research in universities, medical schools, hospitals and other research institutions. The purpose of such schemes is to provide support for work on problems which are capable of solution in a relatively short period of time. ANZCA aims to supplement, complement, and in some cases act as an alternative to NHMRC/HRC. Wherever possible and appropriate ANZCA encourages applicants to also apply to HRC or NHMRC, or to the appropriate body in their home country.

2 Grants
Project Grants and Simulation/Education Grants are awarded to support research proposed by Fellows of ANZCA, or FPM and their collaborators (trainees, scientists, students etc). The policy in relation to chief investigators is:

- The "chief investigator A" (i.e. the first-named investigator) must be a Fellow or registered trainee of ANZCA or FPM, be financial and in good standing with ANZCA.
- If "chief investigator A" is a registered trainee, one of the other chief investigators must be a Fellow of ANZCA or FPM or another suitable supervisor with qualifications acceptable to the Research Committee.
- For Project Grants, other chief investigators may include Fellows or registered trainees of ANZCA or FPM, other medical practitioners, healthcare professionals, scientists, research students, professional research personnel etc.

An individual may only be named as a chief investigator or professional research person on a maximum of TWO applications in any one year. This includes Project Grants, Novice Investigator Grants, the Simulation/Education Grant and the Academic Enhancement Grant. It does NOT include the Douglas Joseph and Lennard Travers Professorships. However, this condition does not apply if an applicant wishes an unsuccessful professorship application to be considered for a project grant and has indicated this by ticking the box on the professorship application form. Fellows and registered trainees must be financial and in good standing with ANZCA or FPM.

Funding is available for research either wholly or partly conducted overseas by Fellows and registered trainees under the following conditions:

1. A Fellow must have a certified ongoing appointment in Australia, New Zealand, Hong Kong, Malaysia or Singapore.
2. A trainee must return to Australia, New Zealand, Hong Kong, Malaysia or Singapore to complete their training program or return to a guaranteed specialist appointment.
3. The researcher who is conducting research overseas must be a chief investigator.
4. The research proposed would normally be completed during the tenure of the grant.
5. The applicant must demonstrate in the application how the project will benefit research in Australia, New Zealand, Hong Kong, Malaysia and/or Singapore.

The investigation will have objectives of mutual interest to ANZCA, the recipient institution, and the investigator. Whilst the grants may specify financial support for individual professional research personnel, the institutions are responsible for administration of the grant.
Awards of grants will normally be announced in October of each year. No payment of the grant will be made until written communication accepting the offer and agreeing to the conditions, and a fully correct tax invoice, are received by the College, and all necessary clearances have been obtained. Funding is made available after January 1 in the following year until December 31 unless an extension of time is successfully requested via the ANZCA Research Committee.

4 Other funding agencies
Liaison between ANZCA and other major funding bodies, both government and private, has been established to preclude duplication of support for identical proposals, as far as possible.

5 Procedure for evaluation of grant applications
The procedure for the evaluation of ANZCA grant applications is modelled on the NHMRC review process. Each application is assessed by three reviewers, one of whom is a spokesperson appointed from the Research Committee, who have been carefully chosen for their expertise in relation to the particular grant application.

To assess the scientific merit of the project and to determine the ability of the investigators to carry out the research, reviewers are requested to (i) rate the grant application and (ii) provide a written report.

Applications are rated on a seven-point scale (ranging from “outstanding” through to “poor”) against a set of six research criteria (track record, scientific merit, originality, design/methods, feasibility and international competitiveness).

The written report addresses the scientific merit of the application (originality of hypothesis, substantiation of objective, soundness of research plan and methodology, and feasibility of the project), the track record of the applicant and the budget, and raises questions on areas of the research which require clarification, including problems and limitations likely to be encountered. The written report is forwarded to the applicant for comment. Applicant responses are limited to three pages only with a 12pt font and a minimum of 1.5cm margins. Pages in excess of the three page limit will not be considered. If the applicant responses are not received by the due date, they will not be considered in the ranking of the application.

The Research Committee then considers all the materials, as presented by the spokesperson. Each member allocates a score out of seven to the grant, these scores are averaged and the final ranking of each grant application is determined. The Research Committee determines a rating score as a cut-off point, below which funding is not available. Those applications that are close to the cut-off score are considered in more detail. An application identified to receive a grant is then exhaustively reviewed to determine the level of funding to be awarded.

Applicants will be notified of the outcome in September following the Research Committee meeting.

Successful Grant Applicants will be expected to participate in reviewing ANZCA grant applications in future years as a condition of accepting the grant.

6 Confidentiality
Applications for grants are received by ANZCA on an “IN CONFIDENCE” basis. This means that the application document will not be released other than in compliance with any waiver or consent given by the applicant.

7 Applications to philanthropic trusts and foundations for research grants
Through the ANZCA Research Foundation, submissions may be made to funding bodies in the philanthropic sector for successful and highly ranked grant applications awarded through the ANZCA peer-reviewed grant process. It should be noted that approved grant funding through the peer-review process is not dependent on an application to the philanthropic sector. Final confirmation of ANZCA funding is subject to completion of any external funding applications for this project that are in progress. The aim of such applications is to continue to increase the pool of available funds for future ANZCA research projects. If an ANZCA grant application is deemed a suitable match to the specific interests of a particular trust or foundation, approval of the CIA will be sought for a submission to be made. The CIA’s input and advice would be sought during the application process. Acceptance of philanthropic trust or foundation support will usually require acknowledgement of that support in publication or presentation of research. This is in addition to the requirement to acknowledge any support provided by ANZCA.
C. GRANT INFORMATION FOR APPLICANTS

Project grants
The maximum amount available for a project grant is $A70,000. Grants are awarded for a period of one or two calendar years following the year of the grant decision.

Funds for subsequent years will only be made available if a satisfactory report on the progress of the grant is provided by September 1 each year. At its discretion, the Research Committee may elect to fund the first year of a grant only and require the applicants to submit a complete project grant application requesting funding for subsequent years.

Scholarships
Scholarship grants are made within the ANZCA project grant scheme. The Fellow or registered trainee seeking salary support must be: 1) the chief investigator or one of a group of chief investigators seeking support for a scientific investigation; 2) a Fellow or trainee of ANZCA or FPM; 3) enrolled in a higher degree (i.e. MD or PhD) and 4) normally working full-time on the research (0.8 FTE or more). Half-time research may be negotiated on a pro-rata basis upon application. The maximum amount available for a project grant that includes a scholarship grant is $A90,000 per year, $A45,000 of which supports the salary of the scholarship grant applicant.

Scholarship grants are usually funded for three years. Funds for years two and three will only be made available if a satisfactory report on the progress of the grant is provided by September 1 each year. At its discretion, the Research Committee may elect to fund the first year of a grant only and require the applicants to submit a complete project grant application requesting funding for subsequent years.

Chief investigators and associate investigators, who are Fellows or trainees of ANZCA or FPM, MAY NOT apply for salary support unless they fulfil the eligibility criteria for a scholarship.

Associate investigators may include Fellows or registered trainees of ANZCA or FPM, other medical practitioners, health care professionals, scientists, research students, professional research personnel etc. Professional research personnel may include nurses, scientists, research assistants and the like. Full-time students, Fellows and trainees may not be included as professional research personnel.

Simulation/Education grants
Simulation and education research are high priorities for the College. In order to specifically encourage research in this area and because of the challenges in comparing clinical and laboratory research with research in education, the College established a specific, named Simulation/Education Grant. Applications should be made using the same form as those for project grants, indicating in the appropriate box that it is for a simulation/education grant. Simulation/education grants will be considered as project grants (thus there is no limit to the number that can be supported), but the highest ranked fundable simulation/education grant will be designated the Simulation/Education grant for that year. The maximum amount for a simulation/education grant is $A70,000.

If the CIA is in doubt as to whether his/her research proposal qualifies for a simulation/education grant please contact the Research and Administration Coordinator.

Scholarship grants are made within the ANZCA project grant scheme. Therefore, researchers in medical simulation and education seeking salary support, as well as general project support, should apply through the ANZCA Project Grant scheme (see above).
INSTRUCTIONS TO APPLICANTS FOR COMPLETING FORM

Indicate the type of application being applied for by ticking the appropriate box.

- Project Grant
- Project Grant including Scholarship
- Simulation/Education Grant

1 Scientific project title
The scientific title will be used to identify the application at all times and should accurately describe the nature of the project. Use no more than 120 characters, including spaces. Additional characters will not be recorded.

2 (a) Chief investigators
"Chief investigator A" (CIA) MUST be a Fellow or registered trainee of ANZCA or FPM. The CIA will be regarded as the contact person for the application and will, in all instances, be assumed to be acting on behalf of, and with the concurrence of, all chief investigators named in this section. An individual may only be named as a chief investigator or professional research person on a maximum of TWO applications in any one year. This includes Project Grants, the Simulation/Education Grant and the Academic Enhancement Grant. It does NOT include the Douglas Joseph and Lennard Travers Professorships. However, this condition does not apply if an applicant wishes an unsuccessful professorship application to be considered for a project grant and has indicated this by ticking the box on the professorship application form. Fellows and registered trainees must be financial and in good standing with ANZCA or FPM. (Add more rows if necessary).

2 (b) Chief investigator for whom a scholarship is requested
If one of the chief investigators is applying for salary support under the ANZCA scholarship scheme, name that individual here.

2 (c) Associate investigators
Associate investigators may be Fellows, trainees, students or professional research personnel, who assist with the research or bring a particular skill (e.g. statistics, assays) to the team. They may or may not be fully conversant with all aspects of the work. Associate investigators do not receive salary support from ANZCA. Add rows to any of the items if necessary.

3 Administering institution
The full name and full address of the institution responsible for administering the grant must appear here (e.g. Royal Prince Alfred Hospital, Missenden Road, Camperdown NSW 2030). While there may be instances where a research project is carried out in more than one location, there can be only one administering institution for each grant.

4 Institution(s) where research will be carried out
The name(s) of the department and name(s) and address(es) of the institution(s) where the proposed research will actually be undertaken is (are) required (e.g. Department of Anaesthesia, Royal Melbourne Hospital VIC 3050). (Add more rows if necessary).

5 Area of research
Specify anaesthesia (01), intensive care medicine (02), pain medicine (03), perioperative medicine (04) or other (05).

6 Keywords
Select up to five keywords or phrases from the list at the end of this guide. If appropriate words are not found in the list, applicants may add their own keywords in this section. The keywords will be used to identify suitable reviewers.
7 Lay description of research
Provide a brief description of the department and/or chief investigator(s), the achievements of the department and/or chief investigator(s), and the proposed research and its significance [suitable for a media release]. No more than one page is allowed. Please provide a lay title.

8 Grant synopsis
This information is used primarily to assign the application for review. This one page synopsis should describe the project and include a description of the aims, significance, context, objectives, methods and likely benefits of the research plan to the research group and the specialty.

Requested non-reviewers: Applicants preferring particular reviewers NOT to be approached to assess their application should attach a letter containing details of up to two non-requested non-reviewers. This letter should be attached to the original application only. These requests will be considered by the ANZCA Research Committee.

9 Research plan
Describe your research project in this section. Do not use more than seven pages in total, including references. Note that the minimum page margin is 2cm and the minimum font size is 10pt. Any additional pages will be removed prior to review.

You must use the headings listed below to describe your research.

9.1 Aims and significance: Use this space exclusively to describe the broad aims and potential significance of the research. Hypotheses to be tested must be clearly stated.

9.2 Background: Describe the significance of the broad area of research, the objectives of the research and the background including scientific aspects.

9.3 Methods: Include details of the experimental design of the project and statistical methods to be used. Include sample size estimations.

9.4 Feasibility: You must provide evidence that the proposed study can proceed in a timely fashion (i.e. recruitment of participants is assured, instruments have been developed and piloted).

9.5 References: References should be provided within the seven-page count. Do not attach copies of any references. When citing references to other work, include the title of the paper.

Explanatory appendices are not permissible, nor is it appropriate to use such phrases as “refer to last year’s application”.

10 Professional research personnel
Professional research personnel may include nurses, scientists, research assistants and the like. Full-time students, Fellows and trainees may not be included as professional research personnel.

Where appropriate, request for professional salaries should be in accordance with the official salary scales (such as NHMRC or nursing scales). Personnel should be named where known. Where the personnel are unknown the required salary should be determined on the basis of the appropriate scale. Requests for new senior research officer positions only must provide a curriculum vitae with the application. Include provision for payroll tax, workers’ compensation insurance, superannuation or other institutional legal liabilities. Nursing awards may also be appropriate for calculating salaries.

Add more rows to any of the tables in this section if necessary and repeat for each named professional research person.

11 Budget items
Please note that applications for more than the maximum amount will be returned.

The budget must be constructed in Australian dollars. The maximum amount available for the project grant is $A70,000 (or $A90,000 if supporting a scholarship) and the maximum amount for the simulation/education grant is $A70,000. Whilst columns are provided for three years, one-year grants are the norm (see above). All items listed in the space provided, are to be classified under these headings:
11.1 **Personnel:** Chief investigators and associate investigators may not receive salary from project grants, unless they are eligible for scholarship support (see above). Requests for professional research personnel salaries including initial, promotion and renewal requests, should be in accordance with the official NHMRC or MRC designations and salary scales, or appropriate nursing awards. Include provision for payroll tax, workers’ compensation insurance, superannuation or other institutional legal liabilities and on-costs.

11.2 **Equipment:** Equipment requests should not include the type of apparatus normally provided from institutional funds (such as equipment used in the normal course of patient care); requests should cover only those items individually costing over $A800, which are essential to the project. Where the cost of a specific item of equipment, plus related accessories, is in excess of $A10,000, a firm written quotation based on current prices, not incorporating any component for customs duty, must be submitted. Applicants should ensure that the institution is prepared to meet all service costs in relation to equipment awarded.

11.3 **Maintenance:** Enter those items not included within other categories, i.e. such items as equipment costing less than $A800, consumables (under major headings), printed materials, microfilms, survey or field expenses and computing charges.

11.4 **Other Items:** Include all other budget items here. ANZCA will consider requests for funding for computer programming and preparation, and storage of data, but will not normally provide funds for the hire of computer time on a computer within the applicant’s institution. Requests for funds for programming, preparation and data storage or the hire of external computer time must be fully justified. Funds for purchase of computer equipment and hire of computer personnel should be itemised under “Equipment” and “Personnel” respectively.

11.5 **Justification of budget:** It is important to note that realistic budgetary details for the whole period are provided, as no supplementary requests will be granted. A genuine assessment is therefore required for funding of the grant. Amounts requested should reflect the real needs of the project.

12 **Chief investigators**

The chief investigator(s) is (are) pivotal to the concept, design and conduct of the research, analysis of the data and/or preparation of the manuscripts. The chief investigator(s) is (are) fully conversant with all aspects of the research. Chief investigators **DO NOT** receive salary support, unless they are applying for a scholarship.

Complete item 13 for each named chief investigator on this application. Start each chief investigator on a new page. Add rows to any of the items if necessary.

12.1 **Contact details:** Please ensure that the details provided are complete and accurate, as this information will be used to communicate with the applicants.

12.2 **Academic qualifications/awards:** Provide details of academic qualifications including university degrees, specialist college diplomas, research or other awards or honours, the institution or body awarding the qualification and the year it was awarded.

12.3 **Current appointments:** List all current positions with the location (institution). Any changes during the lifetime of the grant relating require notification to ANZCA.

12.4 **Previous appointments:** Please list relevant previous positions held.

12.5 **Anticipated absences during grant period:** Should an investigator be absent during the project grant for a period in excess of two months, specify period of absence and give reason.

12.6 **Scholarship details:** Include the nature of the scholarship (initial appointment, reappointment or promotion). Indicate whether you have applied to NHMRC. Applicants are strongly encouraged to apply for salary support from NHMRC as well. Briefly describe the arrangements for the scholarship: where the individual will be based, who will supervise or advise on the research, the higher degree and institution and any other proposed outcomes from the research and the weekly time allocation to the research.
13 Research grant support
The information sought on past, present and future support will assist ANZCA in determining the relationship between various projects and the personnel involved in them, including their time commitment. For this reason, applicants should list ALL projects for which their name is recorded as a chief investigator in each category.

In each category, indicate the year of application, ANZCA RegKey, NHMRC application ID etc, title of grant, chief investigators, time commitment of each named investigator to each grant, period of support and funds for each year. In the column headed Publications, please identify separately, by number, each publication listed by a chief investigator which has resulted directly from each project (i.e. CIA-4: the 4th publication in the list of chief investigator A publications). Do not include the same publication more than once; include only original papers published or accepted for publication in refereed journals. Add more rows to each table if necessary.

13.1 Completed grants: Details of past research grant support should encompass all projects or part projects funded over the previous five year period by all sources of grants (not including the year of application), itemising the level of support for each year. Include project grants, program grants, scholarships etc. Exclude any projects which hold a current commitment (e.g. a three year project currently in its second year), to be itemised under 14.2.

13.2 Current grants: Include details of all currently held grants, including those that have been awarded but have not yet commenced.

13.3 Requested grants: Include this application and all other grant requests relating to this program of research, as well as requests related to other research. Please provide full details of ALL funding from any source. Failure to disclose full information will result in the application being removed from any further consideration by ANZCA. If you apply to another funding agency after submitting this application, you must immediately notify ANZCA in writing.

14 Track Record
14.1 Publications of chief investigators
List, and number consecutively, papers published, in press or finally accepted for publication in refereed journals, by any of the chief investigators (CIA, CIB, CIC, CID etc) in the five years prior to the year of application and in the year of application. The listing must indicate titles of papers, sequence of authors as shown in the paper, first and last pages, name, volume and date of journal; for recent papers not yet published, the date of final acceptance by the journal’s editor is required. Quality as well as quantity of publications will be considered in the assessment of grant applications. Papers in refereed journals in which the chief investigator was not co-author, but which resulted from previous grants, should be listed at the end of that chief investigator’s publications under the title ‘non-chief investigator papers’ (e.g. papers with scientists or PhDs supported by the grant but in which the chief investigator was not an author). Documentary evidence of final acceptance by editors must be made available to ANZCA. Do not include abstracts or papers in preparation or submitted for publication but not yet finally accepted.

Publications resulting directly from a specific project must be identified in the list of completed or current grants and, where applicable, in progress reports or in summary reports, and should be identified as “CIA -5” or “CIB -2”). Asterisk (*) a maximum of five publications per chief investigator, which are considered to best reflect research contributions to date. Please include the citation index for these 5 papers and the impact factor of the journal in which they were published.

14.2 Other items
The chief investigators may list other items for track record consideration. For participation in multi-centre trials, the chief investigator must be the named principal site investigator. The name of the trial, the chief investigator(s) of the trial and the number of patients enrolled at the time of application must be included. For ongoing study in statistics/epidemiology/research methods, please state the institution, name and duration of the course. Other items may include membership of research ethics committees or grant committees, supervision of research students and the like. A maximum of one page for all investigators combined is permitted.
15 Clearance requirements
The Research Committee strongly encourages investigators to apply for ethics committee approval and submit the approvals to the College by **September 1**. If a grant is awarded, funding will not be released until all relevant clearances for the initial project have been received by ANZCA. ANZCA reserves the right to request full ethics committee submissions and correspondence as part of the granting process. In addition, ANZCA requires that clinical trials are pre-registered with the appropriate agency (e.g. NHMRC).

15.1 Research involving humans
(i) Approval of the institutional ethics committee should be sought for ALL projects in humans. In the case of audit or routine testing, the ethics committee may not require a formal application, but will provide a covering letter that must be submitted to the College. Human research, in this context, includes research involving any human tissue, no matter what the source, and also includes research in which there is any intervention (physical or psychological) in the normal lives of humans. Projects supported by ANZCA are expected to conform with the general principles outlined in the NHMRC *National statement on ethical conduct in human research* (2007). (see NHMRC website)

(ii) Under the various privacy laws, any form of experimentation involving humans (including epidemiological research) which uses personal information that is obtained from a National or State Department or Agency must be considered by a Human Research ethics committee (HREC).

(iii) All projects involving the administration to humans of drugs, chemical agents or vaccines need to be considered by the relevant Human Research Ethics Committee (HREC) to assess the appropriateness of their use. Clearance by the HREC is not only required for projects involving the use of imported substances, but also for projects involving the experimental use of locally produced therapeutic substances. ANZCA funds will not be provided unless appropriate clearance for the use of such substances is given. In the case of multi-centred trials, approval must be obtained from the HREC of each institution involved. In the case of drugs that are not approved for use in Australia, New Zealand, Hong Kong, Malaysia and/or Singapore, approval of the appropriate authority must be obtained before funds can be released.

(iv) The official letter or statement of approval from the ethics committee must be forwarded to ANZCA no later than **September 1** each year, or before a tax invoice for funds is sent to the College.

(v) ANZCA should have access, if required, to all information relating to ethical decisions arising from an application and the institutional response to the application. Provisional clearances will not be accepted.

(vi) Under item 15.4, please summarise all the ethical implications of your research program. Do not use more than one page. Include the issues of privacy, and male-female ratios, and the cultural implications of your research (i.e. as they relate to aboriginal populations). Please refer to the NHMRC *National statement on ethical conduct in human research* (2007). Note that it is not sufficient to state that “the NHMRC Statement on Ethical Conduct in Human Research will be observed”. The research plan must include sufficient detail to enable the project to be fully assessed with respect to ethical issues by an independent ethics committee.

15.2 Research involving animals
(i) Projects supported by ANZCA are expected to conform with the provisions and general principles of the NHMRC *Australian code of practice for the care and use of animals for scientific purposes* 8th (Ed) 2013 or the New Zealand equivalent.

(ii) ANZCA requires a statement from the relevant institutional animal experimentation ethics committee that any project involving animal experimentation has been reviewed and is approved by the Committee as complying with the code of practice. It is the applicant’s responsibility to ensure that a copy of his or her project application is referred to the relevant institutional animal ethics committee; it also his or her responsibility to ensure that the completed approval form is forwarded to ANZCA, no later than **September 1** each year, or before the tax invoice for funds is sent to ANZCA.
(iii) ANZCA should have access, if required, to all information relating to ethical decisions arising from an application and the institutional response to that application. Please identify the institutional animal ethics committee to which the application has been or will be referred. Provisional clearances will not be accepted.

(iv) Applicants whose projects involve inbred strains of animals must take action to confirm that the genetic authenticity of the colony has been checked at appropriate intervals.

(v) Ideally the health status of animals should be known and the colony regularly monitored for pathogens which may influence results in the investigator’s particular area of research.

(vi) Under item 15.5, please summarise all the ethical implications of your research program. Do not use more than one page. Include the issues related to the care and welfare of animals. Please refer to the NHMRC Australian code of practice for the care and use of animals for scientific purposes. Note that it is not sufficient to state that “the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes will be observed”. The research plan must include sufficient detail to enable the project to be fully assessed with respect to ethical issues by an independent animal ethics committee. Applications involving animals must contain adequate information to allow assessment of the ethical implications of experiments, particularly where significant pain and/or distress may be caused, where death is likely to occur, or where experiments in Category 4 are to be carried out.

15.3 Other clearances

15.3.1 Genetic manipulation of organisms: Applicants proposing to undertake research involving genetically modified organisms (GMO) must ensure that all the requirements of the Gene Technology Act 2000 and the Gene Technology Regulations 2014 have been met. Information on the Act and Regulations can be found on the Office of the Gene Technology Regulator website (www.ogtr.gov.au). Applicants should seek advice from their institutional biosafety committee (or equivalent) on the level of authorisation required for any GMO research. Clearances from an institutional biosafety committee (or equivalent) must be forwarded to ANZCA prior to release of grant monies.

15.3.2 Use of carcinogenic or highly toxic chemicals: Applicants whose projects involve the use and disposal of potent carcinogenic or other highly toxic chemicals must adhere to the National Occupational Health and Safety Commission guidelines, National Code of Practice for the Preparation of Material Safety Data Sheets 2nd edition. Further information is available from the Safe Work Australian website or equivalent. Such applicants must seek clearance to be forwarded to ANZCA prior to release of grant monies.

15.4 Conflict of interest

Applicants are NOT required to complete the questionnaire but rather are requested to read and understand the ANZCA Conflict of Interest Policy available at: http://www.anzca.edu.au/documents/conflict-of-interest-policy.pdf declare any conflicts, and state how such conflicts will be managed.

16 Progress report on ANZCA grant(s)

A progress report must be provided for each grant being supported by ANZCA at the time of preparing this application and which has listed, as one of the chief investigators, any of the chief investigators of this application. A separate report form should be used for each progress report. It is understood that current projects may not relate to the project proposed in this application. Failure to submit all progress reports may jeopardise its outcome.

At the conclusion of support for each grant, a final report must be submitted to ANZCA. The deadline for this report is within three months of the completion of the project. Each chief investigator on this application, who was listed as a chief investigator on any project that terminated in the December prior to submission of this application, MUST obtain copies of the terminating project’s summary report and append it to this application. Failure to comply with this request may jeopardise the outcome of this application. The final report must include a statement of the expenditure charged to the grant. Unused funds may not be expended on other activities and must be returned to the College.
17 Certification by chief investigators, head of department and of institution

The application is invalid without the signature(s) of all the chief investigator(s). Grants will only be considered for support if the head of department/head of research committee certifies that the facilities available are appropriate to meet the needs of the application (e.g. adequately staffed and equipped laboratories/workshops, secretarial assistance, library resources, research/maintenance support including equipment maintenance, animal housing facilities etc).

When applicants are not formally attached to institutions, they should indicate whether they have access to appropriate facilities to undertake the research proposed.

ANZCA accepts as the head of institutions: the registrars of universities, the directors of independent institutes, and the managers/secretaries or medical superintendents of hospitals.

The head of the institution should note that Statements of Compliance with the NHMRC Australian code of practice for the care and use of animals for scientific purposes 8th (Ed) 2013 and the NHMRC National statement on ethical conduct in human research 2007 (updated 2015) are required to be completed and submitted to ANZCA on request. The head of the institution is also required to certify that the institution has established administrative processes for assuring sound scientific practice in accordance with the NHMRC Australian code for the responsible conduct of research.

18 Referees for scholarship applications

Applicants for scholarships should approach individuals to be referees. The applicant should provide each referee with the form and a complete application. The referee must forward their reference to the applicant to attach to the application before the closing date at 5PM AEDT on April 1, 2017.

Attachments

The attachment should be sent by the applicant to two referees if an investigator is applying for a scholarship.

Checklist

Complete checklist and add to original application.
APPENDIX: KEY WORDS AND PHRASES FOR USE IN ANZCA GRANT APPLICATIONS

These key words are phrases are modified from those used by the journal Anesthesiology. If the key word or phrase that describes your work is not listed here, please list in the key word section of your application.

**STEMS**

**ACID-BASE CHEMISTRY**

**ADDICTION AND DRUG ABUSE**

**AIRWAY and AIRWAY MANAGEMENT**

**AMBULATORY CARE**

**ANAESTHESIA MACHINES and CIRCUITS**

**ANAESTHETICS, GASES**

**ANAESTHETICS, INHALATION**

**ANAESTHETICS, INTRAVENOUS**

**ANAESTHETICS, LOCAL**

<table>
<thead>
<tr>
<th>Key words/phrases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol and alcoholism</td>
</tr>
<tr>
<td>Airway and ETT assessment</td>
</tr>
<tr>
<td>Cervical spine movement</td>
</tr>
<tr>
<td>Endotracheal tubes</td>
</tr>
<tr>
<td>LMA, ILMA and other supraglottic airways</td>
</tr>
<tr>
<td>Laryngeal and pharyngeal function and anatomy</td>
</tr>
<tr>
<td>Aspiration</td>
</tr>
<tr>
<td>Laryngoscopy, direct</td>
</tr>
<tr>
<td>Laryngoscopy, flexible and rigid fiberoptic</td>
</tr>
<tr>
<td>Lightwands and other Indirect methods</td>
</tr>
<tr>
<td>Lung isolation devices</td>
</tr>
<tr>
<td>Tracheostomy and cricothyroidotomy</td>
</tr>
<tr>
<td>Anaesthesia ventilators</td>
</tr>
<tr>
<td>Circuits and vaporizers</td>
</tr>
<tr>
<td>CO(_2) absorbants and humidification</td>
</tr>
<tr>
<td>Waste gases and scavenging</td>
</tr>
<tr>
<td>Nitrous oxide</td>
</tr>
<tr>
<td>Xenon</td>
</tr>
<tr>
<td>Halothane, enflurane and isoflurane</td>
</tr>
<tr>
<td>Desflurane</td>
</tr>
<tr>
<td>Sevoflurane</td>
</tr>
<tr>
<td>Non-Immobilizers</td>
</tr>
<tr>
<td>Other inhalation anaesthetics</td>
</tr>
<tr>
<td>Anaesthetic metabolism and degradation</td>
</tr>
<tr>
<td>Carbon monoxide</td>
</tr>
<tr>
<td>Compound A and fluoride</td>
</tr>
<tr>
<td>MAC</td>
</tr>
<tr>
<td>Uptake and Distribution</td>
</tr>
<tr>
<td>Barbiturates</td>
</tr>
<tr>
<td>Benzodiazepines (and antagonists)</td>
</tr>
<tr>
<td>Etomidate</td>
</tr>
<tr>
<td>Ketamine (and related drugs)</td>
</tr>
<tr>
<td>Butyrophenones</td>
</tr>
<tr>
<td>Alpha2 agonists (as sedatives)</td>
</tr>
<tr>
<td>Propofol</td>
</tr>
<tr>
<td>Computer controlled infusions</td>
</tr>
<tr>
<td>Opioids (as anaesthetic supplements)</td>
</tr>
<tr>
<td>Bupivacaine, lignocaine or mepivacaine</td>
</tr>
<tr>
<td>Levobupivacaine</td>
</tr>
<tr>
<td>Ropivacaine</td>
</tr>
</tbody>
</table>
AUTONOMIC NERVOUS SYSTEM
- Encapsulated agents
- Other local anaesthetics
- Cardiotoxicity
- Seizures
- Baroreflexes
- Catecholamines
- Heart rate variability
- Microneurography
- Parasympathetic nervous system
- Sympathetic nervous system

AWARENESS and RECALL
- Enoxaparin and LMWH
- Heparin and protamine
- Hirudin
- Fibrinolytics
- Coagulation testing
- DIC and other coagulopathies
- Platelets and platelet function
- Aminocaproic and tranexamic acid
- Aprotinin
- Recombinant factor VIIa

BLOOD COAGULATION
- Acute normovolemic hemodilution
- Cell saver and other salvage methods
- Controlled hypotension
- Haemoglobin-based oxygen carriers
- Perfluorocarbons

BLOOD TRANSFUSION, CONSERVATION and SUBSTITUTES
- Mutation and mutagenesis

CANCER and MALIGNANCY
- Cardiac electrophysiology and conduction
- Cardiac rhythm and dysrhythmias
- Cardiac smooth muscle and myocyte function (in vitro)
- Cardiopulmonary bypass
- Circulatory arrest
- Circulatory physiology and hemodynamics
- Congenital heart disease and surgery
- Coronary circulation, myocardial ischemia and infarction
- Cardiac revascularization surgery (CABG etc)
- Myocardial preconditioning and protection
- Reperfusion injury
- Valvular heart disease and surgery
- Ventricular function
- Hypertension
- Pacing, pacemakers and defibrillators

CARDIOVASCULAR DRUGS
- ACE inhibitors
- Alpha2 agonists (CV Actions)
- Angiotensin receptor blockers
- Beta-Adrenergic blockers
- Beta-Agonists
Calcium channel blockers
Other antiarrythmics
Norepinephrine and epinephrine (vasopressors)
Dopamine
Dobutamine
Fenoldepam
Phosphodiesterase inhibitors
Amrinone and milrinone
Nitroprusside and nitroglycerin
Other vasopressors
Vasopressin
Statins

CELL BIOLOGY AND PHYSIOLOGY
Apoptosis
ATP and electron transport
Calcium and calcium signaling
Calcium binding proteins
Gene expression
Mitochondria

CHEMISTRY, BIOPHYSICS AND PHYSICS
Drug related
Equipment related
Procedure related
Compartment syndromes
Other

COMPLICATIONS

CRITICAL CARE
Burns
Trauma care

DERMATOLOGY

ECONOMICS, OR MANAGEMENT and MANPOWER
Trainee evaluation
Simulators

EDUCATION

EMBOLI and EMBOLIC DISORDERS
Amniotic fluid emboli
Fat and particulate emboli
Pulmonary thromboembolism
Venous and arterial gas emboli

ENDOCRINOLOGY
Diabetes mellitus and insulin
Oestrogen
Pheochromocytoma
Renin and angiotensin
Atrial and brain natriuretic peptides

EPIDURAL and SPINAL
Dural-puncture headache and blood patch
Neurologic symptoms and injury
Balance, posture and position sense

EQUIPMENT, TECHNOLOGY AND BIOENGINEERING
Animal care
Brain death and organ harvest
Do Not Resuscitate orders

ETHICS
<table>
<thead>
<tr>
<th>Category</th>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>EYE</td>
<td>Human studies and consent, Eye injuries and blindness, Eye surgery, Intraocular pressure</td>
</tr>
<tr>
<td>FLUIDS, ELECTROLYTES and PLASMA SUBSTITUTES</td>
<td>Hetastarch and pentastarch, Hypertonic saline, Osmolality and oncotic pressure, Serum sodium, potassium and other electrolytes, Lipid and intralipid</td>
</tr>
<tr>
<td>GASTROINTESTINAL PHYSIOLOGY and PATHOPHYSIOLOGY</td>
<td>Gastric reflux and emptying, Intestinal motility, Intestinal permeability, Splanchnic circulation</td>
</tr>
<tr>
<td>GENDER GENETICS and GENETIC DISORDERS</td>
<td>Sickle cell disease, Genetic testing, Gene therapy</td>
</tr>
<tr>
<td>GERIATRICS IMMUNOLOGY, INFLAMMATION and INFECTION</td>
<td>CT scanning, Magnetic Resonance Imaging and fMRI, PET scanning, Ultrasound, Xray</td>
</tr>
<tr>
<td>KIDNEY and BLADDER PATHOPHYSIOLOGY</td>
<td>Bladder function and urinary retention, Renal function testing, Renal failure and dialysis</td>
</tr>
<tr>
<td>LIVER PHYSIOLOGY and PATHOPHYSIOLOGY</td>
<td>Liver blood flow</td>
</tr>
</tbody>
</table>
Liver function tests

MALIGNANT HYPERTHERMIA
Diagnostic testing
Genetics and genotyping

METABOLISM and NUTRITION
Glucose and carbohydrate metabolism
Whole body metabolic rate
Obesity
Protein metabolism

MONITORING (CARDIORESPIRATORY)
Arterial catheters and pressure measurement
Blood volume, systemic
Systolic pressure variation
Cardiac output measurement
Central venous catheterization
Doppler, other
Doppler, precordial
Echocardiography, transoesophageal
Echocardiography, other
Electrocardiography
Expired gas analysis
Gastric tonometry
Oximetry, pulse
Oximetry, mixed venous
Oximetry, other
Pulmonary artery catheterization

MONITORING (CNS)
BIS and similar techniques
Electroencephalography (EEG)
Evoked potentials, auditory
Evoked potentials, motor
Evoked potentials, other
Evoked potentials, somatosensory
Oximetry, jugular venous
Oximetry, transcranial
Transcranial Doppler
Depth of Anaesthesia Assessment

NAUSEA and VOMITING
Antiemetics

NERVE BLOCKS
Brachial and cervical plexus blocks
Celiac plexus block
Lower extremity blocks
Intravenous regional anaesthesia
Other regional techniques
Nerve localization methods
Nerve injury and other complications
Neostigmine and anticholinesterases
Neuromuscular junction
Neuromuscular monitoring
Nondepolarizing agents
Succinylcholine
Myaesthenia Gravis

NEUROPHYSIOLOGY, BRAIN
- Blood brain barrier
- Cerebral blood flow and volume
- Cerebral oedema and intracranial hypertension
- Cerebral ischemia and anoxia
- Cerebral metabolism
- Cerebral protection and preconditioning
- Clinical neuroanaesthesia
- Clinical neurology and neurologic examination
- Head injury
- Hippocampus and hippocampal electrophysiology
- Intracranial pressure and intracranial hypertension
- Neuronal electrophysiology, other

NEUROPHYSIOLOGY, SPINAL CORD
- Dorsal root ganglia
- Spinal cord electrophysiology
- Spinal cord injury
- Spinal cord ischemia
- Spinal cord anatomy
- Spinal cord protection and preconditioning

NEUROPHYSIOLOGY, PERIPHERAL NERVE
- Peripheral nerve injuries
- Growth factors
- Nerve conduction and EMG
- Peripheral nerve electrophysiology

NEUROTRANSMISSION, TRANSMITTERS AND RECEPTORS
- Acetylcholine and receptors
- Adenosine and receptors
- Adrenergic agents and receptors
- Cannabis and cannabinoid Receptors
- Capsaicin and thermal receptors
- Dopamine and receptors
- GABA and receptors
- Glutamate and receptors
- Glycine and receptors
- Neurokinins and receptors
- Nitric oxide and nitric oxide Synthase
- Opioids and opioid receptors
- Serotonin and serotonergic receptors
- Neurotransmitter release and reuptake

NEUROTRANSMISSION and SIGNAL TRANSDUCTION
- G-proteins
- cAMP and cGMP
- Protein kinases

OBSTETRICAL ANESTHESIA
- Caesarean section
- Eclampsia and preeclampsia
- Foetal monitoring and pathophysiology
- Labour and delivery
- Uterine and placental function
- Uterine smooth muscle
OXYGEN and OXYGEN TRANSPORT
- Hypoxia
- Hemodilution (physiology)
- Tissue oxygen tension (PtO2)
- Hyperbaric oxygen

PAIN MANAGEMENT, CLINICAL
- Acupuncture and accupressure
- Chronic pain
- Epidural and other steroid injections
- Neuropathic pain and CRP
- Stellate ganglion blocks
- Lumbar sympathectomy
- Pain assessment techniques
- Patient controlled analgesia
- Postoperative pain
- Headache (NOT PLPH)
- Herpes zoster
- Intraarticular analgesia
- Intrapleural and intraperitoneal local snaesthetics
- Phantom limb pain
- Preemptive analgesia (clinical)
- TENS and related methods
- Spinal cord stimulation
- Epiduroscopy
- Radiofrequency lesions and neurolysis

PAIN-RELATED PHARMACOLOGY
- Alpha 2 Agonists (analgesics)
- Aspirin and Acetominophen
- Baclofen
- COX2 antagonists
- Gabapentin
- Neostigmine
- NMDA antagonists
- NSAIDs
- Opioids
- Opioid antagonists
- Opioid tolerance
- Tramadol
- Nitric oxide

PAIN PHYSIOLOGY, EXPERIMENTAL
- Incisional pain
- Neuropathic pain
- Inflammatory pain
- Pain assessment techniques
- Pain mechanisms, central
- Pain mechanisms, peripheral
- Pain mechanisms, spinal
- Pain models
- Preemptive analgesia (experimental)
- Visceral pain

PATIENT SAFETY and MEDICOLEGAL ISSUES
- Closed claims studies
<table>
<thead>
<tr>
<th>Section</th>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electrical and fire safety</td>
<td>Neurone physiology</td>
</tr>
<tr>
<td>Medicolegal matters</td>
<td>Neonatology</td>
</tr>
<tr>
<td>Neonatology</td>
<td>Pharmacogenetics</td>
</tr>
<tr>
<td>Chronopharmacology/Chronobiology</td>
<td>Psychobiology</td>
</tr>
<tr>
<td>Drug interactions</td>
<td>Psychiatric disorders</td>
</tr>
<tr>
<td>Drug metabolism</td>
<td>Psychopharmacology</td>
</tr>
<tr>
<td>Cytochromes P450</td>
<td>Psychotherapy</td>
</tr>
<tr>
<td>Drug toxicity</td>
<td>Psychotherapy and behaviour</td>
</tr>
<tr>
<td>Liposomes and microcapsule delivery systems</td>
<td>Psychotherapy and behaviour</td>
</tr>
<tr>
<td>Osmotic pumps</td>
<td>Prosthetic implants</td>
</tr>
<tr>
<td>Stereoisomers</td>
<td>Prosthodontics</td>
</tr>
<tr>
<td>Transcutaneous delivery systems</td>
<td>Prosthetics and implants</td>
</tr>
<tr>
<td>Transmucosal delivery systems</td>
<td>Pulmonary rehabilitation</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>Pulmonary rehabilitation</td>
</tr>
<tr>
<td>Anxiety and anxiolysis</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Psychologic, psychometric and behavioural</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Testing</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Electroconvulsive Therapy (ECT)</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>ARDS and lung injury</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Aspiration pneumonia</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Asthma and bronchospasm</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Barotrauma</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>COPD</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Extracorporeal membrane oxygenation</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>High frequency ventilation</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Nitric oxide inhalation</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Pneumonia and lung infections</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>PEEP and CPAP</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Pulmonary oedema</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Pulmonary function testing</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Smoking</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Alveolar macrophage function</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Control of respiration</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Gas exchange</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Pulmonary blood flow</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Respiratory mechanics</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Surfactant</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Tracheal and bronchial smooth muscle</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Ventilation-perfusion matching</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Patient safety and satisfaction</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Quality assurance and management</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Morbidity and mortality</td>
<td>Pulmonary rehabilitation and exercise</td>
</tr>
<tr>
<td>Section</td>
<td>Examples</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Perioperative risk factors</td>
<td>Automated record keeping</td>
</tr>
<tr>
<td>SEIZURES and ANTICONVULSANTS</td>
<td>Cardiac arrest and CPR</td>
</tr>
<tr>
<td>SHOCK AND RESUSCITATION</td>
<td>Sepsis and septic shock</td>
</tr>
<tr>
<td></td>
<td>Haemorrhagic and hypovolemic shock</td>
</tr>
<tr>
<td>SKELETAL MUSCLE</td>
<td>Circadian rhythm</td>
</tr>
<tr>
<td>SLEEP and SLEEP DISORDERS</td>
<td>Sleep apnoea</td>
</tr>
<tr>
<td></td>
<td>Sleep deprivation</td>
</tr>
<tr>
<td>STUDY DESIGN AND TECHNIQUES, LABORATORY</td>
<td>Autoradiography</td>
</tr>
<tr>
<td></td>
<td>Brain slices</td>
</tr>
<tr>
<td></td>
<td>Histopathology and histochemistry</td>
</tr>
<tr>
<td></td>
<td>Cultured cells and tissues</td>
</tr>
<tr>
<td></td>
<td>Laser Doppler Flowmetry</td>
</tr>
<tr>
<td></td>
<td>Microdialysis</td>
</tr>
<tr>
<td></td>
<td>Patch clamping</td>
</tr>
<tr>
<td></td>
<td>PCR</td>
</tr>
<tr>
<td></td>
<td>Receptor binding</td>
</tr>
<tr>
<td></td>
<td>Recombinant methods</td>
</tr>
<tr>
<td></td>
<td>Transgenic and knockout animals</td>
</tr>
<tr>
<td></td>
<td>Isobolographic analysis</td>
</tr>
<tr>
<td></td>
<td>Analytic chemistry (chromatography etc)</td>
</tr>
<tr>
<td></td>
<td>Molecular modeling</td>
</tr>
<tr>
<td>STUDY DESIGN AND TECHNIQUES, CLINICAL</td>
<td>Clinical trial</td>
</tr>
<tr>
<td></td>
<td>Epidemiology</td>
</tr>
<tr>
<td></td>
<td>Mathematical modeling</td>
</tr>
<tr>
<td></td>
<td>Metaanalysis</td>
</tr>
<tr>
<td></td>
<td>Statistics</td>
</tr>
<tr>
<td></td>
<td>Survey</td>
</tr>
<tr>
<td>SURGERY, MISCELLANEOUS</td>
<td>Laparoscopy</td>
</tr>
<tr>
<td></td>
<td>Neurosurgery</td>
</tr>
<tr>
<td></td>
<td>Oral surgery</td>
</tr>
<tr>
<td></td>
<td>Orthopaedic surgery</td>
</tr>
<tr>
<td></td>
<td>Joint Replacement surgery</td>
</tr>
<tr>
<td></td>
<td>Otolaryngology</td>
</tr>
<tr>
<td></td>
<td>Plastic surgery</td>
</tr>
<tr>
<td></td>
<td>Aortic aneurysm (abdominal and thoracic)</td>
</tr>
<tr>
<td></td>
<td>Carotid endarterectomy</td>
</tr>
<tr>
<td></td>
<td>Thoracic anaesthesia and surgery</td>
</tr>
<tr>
<td></td>
<td>Vascular surgery</td>
</tr>
<tr>
<td></td>
<td>Other surgical procedures</td>
</tr>
<tr>
<td>TEMPERATURE REGULATION and MANAGEMENT</td>
<td>Hypothermia</td>
</tr>
<tr>
<td></td>
<td>Hyperthermia and fever</td>
</tr>
<tr>
<td></td>
<td>Shivering</td>
</tr>
<tr>
<td>TRANSPLANTATION</td>
<td>Heart transplantation</td>
</tr>
<tr>
<td></td>
<td>Liver transplantation</td>
</tr>
</tbody>
</table>
Lung transplantation
Immunosuppressants

VASCULAR PHYSIOLOGY

Rheology and viscosity
Endothelium
Endothelin
Leukocyte adhesion
Nitric oxide, nitric oxide synthase and EDRF
Selectins
Vascular smooth muscle
Vascular growth factors
Vascular electrophysiology
Microcirculation